Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two KRAS inhibitors that target the G12C mutation showed promising anti-tumor activity against metastatic colorectal cancer and pancreatic cancer, respectively, in early-phase trials.
Technological innovation and changes to regulation are disrupting the hearing health sector, with implications for data privacy, product safety and accessibility, and provide challenges and opportunities for equitable hearing health.
A desire for better work conditions and real-world impact are behind the movement, which may hinder academic clinical trials while leading to beneficial collaborations.